Developing a blood test to track ALS progression and treatment response
Official title: Blood-based Biomarker for Characterizing Progression and Therapeutic Response in Amyotrophic Lateral Sclerosis
Funded at Neurodex INC · NIH-11005933 · Data updated 2026-11-12
This study is looking at a new blood test that measures a marker called TDP43 to help track how ALS and related conditions like Alzheimer's are progressing, with the goal of improving care and treatment for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neurodex INC NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $2,147,016 |
| NIH project number | 1R44NS137901-01A1 |
| Project ID | NIH-11005933 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with amyotrophic lateral sclerosis (ALS) or related dementias.
✕Less likely to help
Patients with conditions unrelated to ALS or related dementias may not benefit from this research.
What this research studies
This research focuses on creating a blood-based biomarker called TDP43, which could help in understanding the progression of amyotrophic lateral sclerosis (ALS) and related dementias like Alzheimer's disease. The approach involves isolating neuron-derived extracellular vesicles from blood samples to measure TDP43 levels, which may indicate disease progression and response to therapies. By improving the accuracy of ALS diagnostics and treatment monitoring, this research aims to enhance patient care and clinical trial efficiency.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnostics and better treatment monitoring for patients with ALS and related dementias.
How similar studies have gone: Previous research has shown promise in using blood-based biomarkers for neurological conditions, indicating potential success for this novel approach.
Where this research is happening
-
Neurodex INC
Arlington, United States Active
Researchers
- Principal investigator: Eitan, Erez — Neurodex INC
- Study coordinator: Eitan, Erez
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Understanding how work exposures and genes influence ALS risk
A study is building a long-term group of people at higher risk for ALS to see how their jobs, exposures at work, and genes together affect if and when the disease might develop.
-
NUZ-001: a treatment option for ALS to protect nerve cells
A small molecule called NUZ-001 is being tested to help people with ALS by improving cell systems that keep proteins balanced and prevent harmful protein clumps.
-
Alpha5 integrin's role in ALS: how a cell switch worsens disease
Aims to understand how a specific protein called alpha5 integrin in immune cells affects ALS progression and whether blocking it can help extend life.
-
C9orf72 ALS/FTD Prevent: prepping for future treatment
This grant aims to get ready for a preventive treatment for people who carry the C9orf72 genetic change that can lead to ALS or frontotemporal dementia.
-
Air pollutants and ALS: mapping environmental links to motor neuron disease
This NIH grant explores whether different air pollutants are linked to the development of ALS and uses a large U.S. data set to look for environmental risk factors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.